MeSH tree: D12.776.377.715.548.114.224.200.875
Researchers at MIT and Stanford University have developed a new way to stimulate the immune system to attack tumor cells, using a strategy that could make cancer immunotherapy work for many more patients.
Dec 16, 2025
0
47
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending ...
Dec 10, 2025
0
0
The ABC Global Alliance today launched the Advanced Breast Cancer (ABC) Global Decade Report 2015–2025—a global assessment revealing a decade of remarkable scientific progress that has transformed ABC care for some patients ...
Nov 5, 2025
0
0
The U.S. Food and Drug Administration (FDA) announced Wednesday that it will relax certain rules for approving low-cost versions of some high-priced medications, in an effort to speed up access to cheaper alternatives.
Nov 1, 2025
0
1
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs)—can dramatically improve outcomes for patients with ...
Oct 20, 2025
0
0
Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible treatment. Their decision is informed by a comprehensive molecular profile of the patient's cancer ...
Jun 5, 2025
0
6
Death rates from breast cancer will fall in 2025 in every age group in the EU and the UK apart from in EU patients aged 80 years and older. In these older patients, overall mortality rates from the disease are predicted to ...
Mar 11, 2025
0
0
A team led by the Institute for Bioengineering of Catalonia (IBEC) and the Hospital del Mar Research Institute has developed the MIRO (Micro Immune Response On chip), a device that allows researchers to replicate the characteristics ...
Feb 6, 2025
0
26
Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF genes (RAS/BRAF wild-type) are typically treated with EGFR inhibitors. For those whose tumors also ...
Jan 29, 2025
0
0
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared ...
Jan 15, 2025
0
9
